REG - ABCAM Plc - Director/PDMR Shareholding
For best results when printing this announcement, please click on the link below:
http://pdf.reuters.com/Regnews/regnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20100316:nRSP6897Ia
RNS Number : 6897I
ABCAM Plc
16 March 2010
For immediate release 16 March 2010
16 March 2010
("Abcam" or "the Company")
Director's Dealings
Cambridge, UK: Abcam plc (AIM: ABC), the rapidly growing bioscience company that markets antibodies via its own online
catalogue, announces the following transactions undertaken by Directors of the Company:
On 16 March 2010, Jim Warwick, an Executive Director of the Company, exercised share options over 22,142 ordinary shares of
1 pence each in the Company at an exercise price of 280 pence per share. Following this transaction, Mr Warwick's total
beneficial interest in the Company is 880,052 ordinary shares representing approximately 2.45 per cent. of the current
issued share capital of the Company.
For further information please contact:
Abcam + 44 (0) 1223 696000
Jonathan Milner, Chief Executive Officer
Jeffrey Iliffe, Chief Financial Officer
Numis Securities + 44 (0) 20 7260 1000
Michael Meade / Nick Westlake - Nominated Adviser
James Black - Corporate Broking
Buchanan Communications + 44 (0) 20 7466 5000
Mark Court / Mary-Jane Johnson / Stasa Filiplic
Buchanan Communications
+ 44 (0) 20 7466 5000
Mark Court / Mary-Jane Johnson / Stasa Filiplic
Notes for editors:
About Abcam plc
Abcam is a producer and distributor of research-grade antibodies headquartered in Cambridge, United Kingdom, with
subsidiaries in Cambridge, Massachusetts, Tokyo and Hong Kong. Abcam was admitted to AIM in November 2005 and trades under
the ticker symbol ABC. The Company produces and distributes its own and third-party produced antibodies and related
products to academic and commercial users throughout the world. Product ordering is available through the Company's website
www.abcam.com, where customers are also able to access up-to-date and detailed technical product data sheets. All the
antibodies are sold under the Abcam brand name. Abcam's mission is to develop the largest catalogue of the best antibodies
in the world, with the vision of becoming a global leader in the wider protein detection and regulation markets. Abcam now
has a rapidly growing online catalogue and as at 31 December 2009 it contained 57,960 products, most of which are
antibodies, from over 250 suppliers. Abcam employs 250 staff in its four operating companies.
This information is provided by RNS
The company news service from the London Stock Exchange
back to RNS news